ArticleCell reports2013
Bisphosphonates target B cells to enhance humoral immune responses.
Article in Cell reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination.Immunology letters · 2024Trial
- Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.JHEP reports : innovation in hepatology · 2024Article
- Biomaterial engineering strategies for B cell immunity modulations.Biomaterials science · 2024Review
- The interplay of drug therapeutics and immune responses to SARS-CoV-2.Cellular & molecular immunology · 2024Review
- Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.Frontiers in immunology · 2023Article
- Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19.Pharmacological research · 2022Article
- Review
- Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.Progress in lipid research · 2021Review
- T-Cell Mediated Inflammation in Postmenopausal Osteoporosis.Frontiers in immunology · 2021Review
- Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection.The Journal of experimental medicine · 2020Article
- Article
- The Suppressive Attitude of Inflammatory Monocytes in Antiviral Antibody Responses.Viral immunology · 2020Review
- Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4Nature immunology · 2020Article
- Dynamics and genomic landscape of CD8Nature · 2019Article
- Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.Orthopaedic surgery · 2019Article
- Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma.World journal of surgery · 2019Article
- Viral subversion of B cell responses within secondary lymphoid organs.Nature reviews. Immunology · 2018Review
- Immune-mediated syndromes following intravenous bisphosphonate therapy.Inflammopharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant-like activity in the absence of CD4(+) and γδ T cells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll-like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.